In-vitro antibiofilm activity of polycaprolactone- poly (lactic-co-glycolic acid) nanofibers loaded amphotericin B, antimicrobial peptide LfcinB (21–25)Pal and zinc oxide for local treatment of periodontitis associated with obstructive sleep apnea

• DOI: 10.1016/j.jddst.2024.105522
• Publication Date: 2024-02-29T09:45:10Z
• Authors: Mayra A. Téllez C...; Jean C. Villamil ...; Nelly S. Roa Molina; Liliana Otero; Zuly Jenny Rivera...; Javier García Cas...; Claudia M. Parra ...; Maria E. Cortés
• Keywords: PLGA; Viability assay; Electrospinning

Periodontitis has been linked to obstructive sleep apnea (OSA). The stage III periodontitis is more prevalent in OSA severe and the oral microbiome changes due an increase periodontal pathogenic bacteria C. albicans. Nanofiber drug delivery systems may be used for local antimicrobial therapy against microorganisms related OSA. aim of present study was manufacture PCL/PLGA nanofibers incorporating antifungal, Amphotericin B (AMB); peptide, LfcinB (21–25)Pal (P61); zinc oxide (ZnO), inhibition vitro polymicrobial biofilms. Nanofibers (Nf) were produced by electrospinning method: Nf loaded with: AMB (Nf 1), AMB-ZnO 2), P61 3), P61–ZnO 4), AMB-P61 5), AMB-P61-ZnO 6) ZnO 7). Different methods physically chemically characterize nanofibers. cell viability human ligament fibroblasts (HPdLF) treated with higher than 50%, demonstrating biocompatibility obtained. anti-biofilm activities assessed using qualitative quantitative analyses. Nine viability, Candida albicans biofilm formation significantly inhibited 6, this effect increased exposure time (72 h). AMB-P61-ZnO-loaded nanofiber offer a promising strategy treating localized cases those apnea.